FDA documents shed light on chaotic COVID decision-making during Trump administration
Internal FDA documents suggest the need for clearer lines of authority to manage emergency response
Internal FDA and White House communications released by FDA in response to a Freedom of Information Act request provide a glimpse into the in-fighting, leaking and chaotic decision-making during some of the most fraught moments of the pandemic during the Trump administration.
The documents feature the controversies over emergency use authorizations (EUAs) for convalescent plasma and hydroxychloroquine, highlighting the role of the White House, celebrities, and disputes within the administration in making decisions that were at the heart of the U.S. response to the pandemic. ...